» Articles » PMID: 20135684

Isolation of a Highly Myogenic CD34-negative Subset of Human Skeletal Muscle Cells Free of Adipogenic Potential

Abstract

The differentiation of multipotent cells into undesirable lineages is a significant risk factor when performing cell therapy. In muscular diseases, myofiber loss can be associated with progressive fat accumulation that is one of the primary factors leading to decline of muscular strength. Therefore, to avoid any contribution of injected multipotent cells to fat deposition, we have searched for a highly myogenic but nonadipogenic muscle-derived cell population. We show that the myogenic marker CD56, which is the gold standard for myoblast-based therapy, was unable to separate muscle cells into myogenic and adipogenic fractions. Conversely, using the stem cell marker CD34, we were able to sort two distinct populations, CD34(+) and CD34(-), which have been thoroughly characterized in vitro and in vivo using an immunodeficient Rag2(-/-)gamma(c) (-/-) mouse model of muscle regeneration with or without adipose deposition. Our results demonstrate that both populations have equivalent capacities for in vitro amplification. The CD34(+) cells and CD34(-) cells exhibit equivalent myogenic potential, but only the CD34(-) population fails to differentiate into adipocytes in vitro and in vivo after transplantation into regenerative fat muscle. These data indicate that the muscle-derived cells constitute a heterogeneous population of cells with various differentiation potentials. The simple CD34 sorting allows isolation of myogenic cells with no adipogenic potential and therefore could be of high interest for cell therapy when fat is accumulated in diseased muscle.

Citing Articles

Intermuscular adipose tissue in obesity and related disorders: cellular origins, biological characteristics and regulatory mechanisms.

Zhang T, Li J, Li X, Liu Y Front Endocrinol (Lausanne). 2023; 14:1280853.

PMID: 37920255 PMC: 10619759. DOI: 10.3389/fendo.2023.1280853.


Botulinum Toxin Treatment of Adult Muscle Stem Cells from Children with Cerebral Palsy and hiPSC-Derived Neuromuscular Junctions.

Costamagna D, Bastianini V, Corvelyn M, Duelen R, Deschrevel J, De Beukelaer N Cells. 2023; 12(16).

PMID: 37626881 PMC: 10453788. DOI: 10.3390/cells12162072.


Muscle stem cells and rotator cuff injury.

Gupta R, Rao R, Johnston T, Uong J, Yang D, Lee T JSES Rev Rep Tech. 2023; 1(3):186-193.

PMID: 37588948 PMC: 10426486. DOI: 10.1016/j.xrrt.2021.05.001.


Cell shape characteristics of human skeletal muscle cells as a predictor of myogenic competency: A new paradigm towards precision cell therapy.

Desprez C, Danovi D, Knowles C, Day R J Tissue Eng. 2023; 14:20417314221139794.

PMID: 36949843 PMC: 10026113. DOI: 10.1177/20417314221139794.


An engineered multicellular stem cell niche for the 3D derivation of human myogenic progenitors from iPSCs.

Mashinchian O, De Franceschi F, Nassiri S, Michaud J, Migliavacca E, Aouad P EMBO J. 2022; 41(14):e110655.

PMID: 35703167 PMC: 9289707. DOI: 10.15252/embj.2022110655.